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Abstract
Depression is one of the leading causes of morbidity in the world and significantly affects
the lives of people suffering from it. The exact cause of depression has not been established
and it is believed to be a complex play between various social, biological, environmental,
personal factors. A relatively rare but distinct cause includes pharmacological agents.
In this case report, we describe the case of a 17-year-old girl who developed depression
with psychotic symptoms on two occasions, both preceded by a history of Isotretinoin use.
She was admitted and treated with anti-psychotics and psychotherapy with significant
improvement in her mental state.
There is no global consensus and direct scientific evidence establishing causality but many
case reports are present in medical literature showing association between depression and
Isotretinoin use. Therefore, it is important for clinicians to exercise caution when prescribing
Isotretinoin to vulnerable groups.
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Consent
Consent was obtained from the parents as patient is a minor. Assent was also obtained from
the patient.

Introduction
Depression is one of the most common mental health condition affecting patients of all
ages. About a quarter billion people are estimated to be suffering from it with women
affected more frequently than men. It is a serious condition, severely affecting the quality of
life of the patient and of those around them. A study finds that Depression accounts for
nearly half of all psychiatric consultations and approximately 12% of all admissions [1].
Access to help continues to be limited which explains the fact that nearly 700,000 people
die to suicide every year. About 75% people suffering with depression in low- and middleincome countries do not have access to any form of medical help. Even when available, help
is difficult to access due to social stigma, guilt, fear, financial condition, limited resources
etc.
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Depression is diagnosed with the help of criterion established by International Statistical
Classification of Diseases (ICD), edition 10. Depressive disorder is covered under chapter V,
section F32 [2].
Symptoms include – low mood, loss of interest in pleasurable activities, significant weight
loss/gain or appetite increase/decrease, sleep disturbance, tiredness/ low energy,
worthlessness/guilt, impaired concentration, suicidal ideation, etc. The symptoms should be
causing significant impairment to psycho-social functioning and must not be explained by
other medical conditions or use of drugs. Some patients also develop somatic
manifestations in the form of myalgia, abdominal pains, headaches etc.
Depression is caused by a complex interplay between many social, personal, environmental,
psychological and biological factors. Most experts believe that the cause is multifactorial.
The involvement of brain neurotransmitters like Serotonin, Dopamine, Norepinephrine and
regions like Amygdala and Hippocampus have been established before [3]. A relatively less
known cause includes drugs. Some of these drugs include Beta Blockers, Calcium Channel
Blockers, Oral Contraceptive Pills, Testosterone, Anti-Epileptics, ACE inhibitors, Angiotensin
Receptor Blockers, Corticosteroids, Alpha and Beta interferons [4].
Another drug known to cause depression is Isotretinoin, being described in a few hundred
case reports. It has been approved by FDA for treatment of nodulo-cystic acne and is found
to be highly efficacious. In 1998, the FDA issued a warning about the potential association
between Isotretinoin and Depression however it also admitted that there was no hard
evidence for the same. Currently, the only evidence of possible link between Isotretinoin
and Depression comes from case reports with the association still being controversial in
clinical practice.
In this case report, we describe a case of a 17-year-old girl diagnosed with Depression
secondary to Isotretinoin use.

Case presentation
A 17-year-old girl, only child from 3rd degree consanguineous parents presented to the
Psychiatry OPD with complaints of sadness, crying spells, irritability, suspiciousness and
decreased sleep for 2 days. The parents also report violent behavior without
warning/reason including slapping and pushing. The patient reported stress of examinations
as the precipitating factor. She expressed frustration with her parents and attributed their
lack of education for their apparent inability to understand her. Further history elicited
suicidal ideation, delusion of grandiosity, delusion of persecution, delusion of reference and
jealousy. On interviewing, patient was found to be short tempered, irritable and sensitive to
criticism. Patient also showed high levels of Neuroticism, Mood lability and
Conscientiousness.
Patient had a previous episode with similar complaints in February of 2022. She also had
flight of speech, hyperhidrosis, decreased need for sleep, harsh and abusive speech, anger,
decreased appetite and increased activity levels. At that time, she was admitted and treated
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with Olanzapine, Amisulpride and Trihexyphenidyl. She discontinued medicines 3 months
back due to weight gain and feeling symptomatically better. Patient also has menstrual
irregularities and was diagnosed with PCOS earlier.
Patient expressed low self-esteem with respect to her weight and acne that started several
years ago. The patient started taking Isotretinoin for the same about 1 year ago. The
consumption of Isotretinoin seems to be temporally associated with her episodes. The
timeline of events is shown in figure 1.

Figure 1 – Timeline of events

Kirby’s examination was done as the patient was uncooperative and it was normal except
spontaneous episodes of crying and distressed facial expressions.
General and systemic examination was found to be normal. Laboratory investigations were
also found to be normal.
Patient was initiated with Psychotherapy and treated with oral Olanzapine 10 mg once a day
and oral Amisulpride 100 mg twice a day with gradual improvement in symptoms. She and
her parents were counselled regarding future use of Isotretinoin.

Discussion
Depression is a serious and common illness, affecting millions of people. It can lead to
suicide which is one of the most common causes of death, particularly in the young-adult
population.
Patients can develop symptoms like sadness, guilt, alterations in sleep cycle, alterations in
appetite, suicidal ideation etc. In some cases, patients may develop even more serious
symptoms, like Psychosis characterized by delusions, hallucinations, disconnect with reality
etc. Patients who have Depression with Mania (flight of ideas, pressured speech,
hyperarousal, anger, lack of need for sleep etc.) are diagnosed with bipolar disorder. This
condition is treated slightly differently than depression alone as use of anti-depressants can
precipitate an episode of mania.
In this particular case, we explore Depression with psychotic symptoms secondary to the
use of Isotretinoin. The patient reported displeasure over acne on her face, for which she
started taking Isotretinoin. As seen in the timeline in figure 1, the patient developed an
episode of Depression with psychosis within a few days of stopping Isotretinoin. This is
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noted to have happened twice. It is interesting to note that the ‘stoppage’ of the drug and
not its introduction seemed to have precipitated these episodes.
Naranjo et al [5] established a simple guide for classifying such drug – score of >9 implies
definite ADR and <2 implies unlikely ADR. We used this scale and got a score of 5 (Probable).
The same can be seen in figure 2.

Figure 2 – Our results from the Modified Naranjo scale for ADR – Sourced from Evidencio TM
from https://www.evidencio.com/models/show/661

Isotretinoin (13-cis-retinoic acid) has been successfully used for the treatment of acne for
over 30 years but the association between Isotretinoin and Depression has been a cause of
concern for a while and there is contradicting information in the literature. While the FDA
has issued a warning suggesting that the Isotretinoin may be associated with Depression, a
systematic review by Li et al [6] showed improvement of symptoms of Depression in those
who were actually taking Isotretinoin. Another paper by Bremner [7] showed that neuropsychiatric side effects, including depression are strongly associated with Isotretinoin and
that caution needs to be exercised while prescribing to vulnerable groups.
Clinicians need to be careful while prescribing Isotretinoin to vulnerable groups and counsel
patients about the risk of neuro-psychiatric adverse events until any association is
conclusively disproven through well designed studies.

https://rescon.jssuni.edu.in/djcm
DOI: 10.55691/2582-3868.1118

4

Karkra et al.: Depression secondary to Isotretinoin

References
1. Kuo DC, Tran M, Shah AA, et al.. Depression and the suicidal patient. Emerg Med Clin
North Am 2015;33:765–78. 10.1016/j.emc.2015.07.005

2. International Statistical Classification of Diseases and Related Health Problems 10th
3.

4.
5.

6.

7.

Revision [Internet]. World Health Organization; [cited 2022Nov11]. Available from:
https://icd.who.int/browse10/2019/en#/F32
What causes depression? [Internet]. Harvard Health. 2009 [cited 2022 Nov 7].
Available from: https://www.health.harvard.edu/mind-and-mood/what-causesdepression
Rogers D, Pies R. General medical with depression drugs associated. Psychiatry
(Edgmont). 2008;5(12):28-41.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for
estimating the probability of adverse drug reactions. Clinical Pharmacology and
Therapeutics. 1981;30(2):239–45.
Li C, Chen J, Wang W, Ai M, Zhang Q, Kuang L. Use of isotretinoin and risk of
depression in patients with acne: a systematic review and meta-analysis [published
correction appears in BMJ Open. 2019 Mar 15;9(3):e021549corr1]. BMJ Open.
2019;9(1):e021549. Published 2019 Jan 21. doi:10.1136/bmjopen-2018-021549
J. Douglas Bremner, Isotretinoin and neuropsychiatric side effects: Continued
vigilance is needed, Journal of Affective Disorders Reports, Volume 6, 2021, 100230,
ISSN 2666-9153, https://doi.org/10.1016/j.jadr.2021.100230

Published by Research Connect,

5

